Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

FDA Real-Time Clinical Trials Shock Pharma Industry, Expose Hidden Compliance Risks Across Systems

The FDA has launched a real-time clinical trial monitoring initiative in the United States, enabling regulators to access live trial data to accelerate drug development and approval. Reported by PharmaVoice on May 13, 2026, the move highlights a growing shift
  • News
FDA Real-Time Clinical Trials Shock Pharma Industry, Expose Hidden Compliance Risks Across Systems

Calibration in Pharma Industry in 2026: Standards, Procedures, and GMP Compliance Requirements

This article explains how GMP certified supplements ensure safety, quality, and regulatory compliance through strict manufacturing controls. It also shows how inspectors evaluate systems and how consumers can identify trusted products in highly regulated supplement markets.
  • Blog, Quality Management System
Laboratory scene demonstrating cGMP certified facilities supplements with quality control documentation, supplement testing, and inspection-based safety procedures.

Tavneos in Crisis — FDA Accuses Amgen of Data Manipulation

The U.S. Food and Drug Administration (FDA) has escalated its regulatory dispute with Amgen over the autoimmune drug Tavneos, accusing the company of manipulating clinical trial data and moving toward potential market withdrawal. The case, centered on alleged data integrity
  • News
Tavneos in Crisis — FDA Accuses Amgen of Data Manipulation

GMP Certified Supplements in 2026: Safety Standards, Quality Assurance, and How to Identify Trusted Products

This article explains how GMP certified supplements ensure safety, quality, and regulatory compliance through strict manufacturing controls. It also shows how inspectors evaluate systems and how consumers can identify trusted products in highly regulated supplement markets.
  • Blog, Quality Management System
Laboratory scene demonstrating cGMP certified facilities supplements with quality control documentation, supplement testing, and inspection-based safety procedures.

Compliant Pharma Sites Fail Annex 1 Inspections, GMP Approval Is No Longer Enough

A recent industry analysis highlights that many pharmaceutical manufacturing sites still fail EU GMP Annex 1 inspections despite passing traditional GMP audits. Published on 15 May 2026 by industry analyst Dobrin Kolarov, the report shows that regulators now prioritize real-time
  • News
Compliant Pharma Sites Fail Annex 1 Inspections, GMP Approval Is No Longer Enough

Data in GMP in 2026: Data Integrity, Compliance Requirements, and Inspection Readiness Explained

This article explains how data in GMP is controlled across its lifecycle, focusing on pharmaceutical data integrity, audit trail review, and electronic records compliance. It highlights regulatory expectations under ALCOA+ principles, FDA guidance, and Annex 11 requirements for inspection readiness.
  • Blog, Validation and Qualification
Pharmaceutical laboratory scene showing digital systems and documentation processes related to GMP data integrity, audit trail review, and electronic records compliance under Annex 11 and 21 CFR Part 11 requirements.

15,800 Drugs Hit by Japan Price Cuts, Pharma Margins Under Pressure

Japan’s FY26 National Health Insurance (NHI) drug price revision has taken effect following analysis by GlobalData released on May 8, 2026. The policy cuts prices across nearly 15,800 medicines by an average of 4.02% and expands the G1 repricing system.
  • News
15,800 Drugs Hit by Japan Price Cuts, Pharma Margins Under Pressure

FDA Leadership Shakeup Raises Concerns, Over Drug Approval Stability

A senior leadership change is unfolding inside the U.S. Food and Drug Administration as Tracy Beth Hoeg, acting head of the agency’s drug evaluation center, is expected to leave after the resignation of FDA Commissioner Marty Makary in Washington, according
  • News
FDA Leadership Shakeup Raises Concerns, Over Drug Approval Stability

Process Deviations in Pharma for GMP Compliance in 2026: Root Cause Analysis, Investigation, and CAPA Guide

Process deviations in GMP environments require structured investigation, accurate documentation, and effective CAPA closure. This article explains how quality teams strengthen deviation management, improve data integrity compliance, and reduce FDA inspection risks through risk-based control strategies and systematic lifecycle handling.
  • Blog, Quality Management System
GMP audit trail deviation control workflow showing quality specialists analyzing deviation reports, CAPA records, and data integrity documentation in a regulated pharmaceutical environment.

FDA Warning Letter to Simtra Exposes Sterile Contamination Risks, GMP Failures Raise Compliance Concerns

The U.S. Food and Drug Administration issued a warning letter to Simtra Biopharma Solutions after an inspection revealed significant contamination-related GMP violations at its sterile manufacturing facility in Halle, Germany. Inspectors identified repeated microbial recoveries, aseptic processing failures, and weak
  • News
FDA Warning Letter to Simtra Exposes Sterile Contamination Risks, GMP Failures Raise Compliance Concerns